Quamatel, 20 mg 28 pcs.

Quamatel is a blocker of histamine H2-receptors.

It reduces basal and stimulated by gastrin, pentagastrin, betazol, caffeine, histamine, acetylcholine and physiological vagus reflex secretion of hydrochloric acid.

The pH increases and pepsin activity decreases. It has practically no effect on gastrin levels on an empty stomach and after meals. It does not affect gastric motility, exocrine activity of the pancreas, blood circulation in the portal system, hormone levels, and has no antiandrogenic effect.

Famotidine has little effect on microsomal liver enzymes.

After oral administration the action comes within 1 h, the maximum action is within 3 h after administration, the duration of effect varies within 12-24 h, depending on the dose.

The drug in the form of lyophilisate for preparation of solution for intravenous injection after a single dose of 20 or 40 mg in the evening suppresses basal and nocturnal secretion for 10-12 hours.

Indications

Active ingredient

Composition

1 tablet contains:

How to take, the dosage

In gastric and duodenal ulcer in the acute phase Quamatel is prescribed in a dose of 40 mg once a day before bedtime or 20 mg twice a day, morning and evening. If necessary, the daily dose may be increased to 80-160 mg. The average duration of the course of treatment is 4-8 weeks.

In order to prevent exacerbations of gastric and duodenal ulcer, Kvamatel is prescribed in a dose of 20 mg once daily before bedtime.

In reflux esophagitis the drug is prescribed in a dose of 20 mg 2 times daily (morning and evening) for 6 weeks; if necessary, 40 mg 2 times daily.

In Zollinger-Ellison syndrome the initial dose is 20-40 mg every 6 hours; if necessary, the daily dose may be increased to 240-480 mg. The duration of use depends on the clinical condition of the patient.

In order to prevent aspiration of gastric contents during general anesthesia Quamatel is prescribed in dose of 40 mg the day before surgery and/or in the morning of the day of surgery.

Interaction

Due to the increase in the pH of the stomach contents, Quamatel concomitantly reduces absorption of ketoconazole and itraconazole; increases absorption of amoxicillin and clavulanic acid.

Antacids and sucralfate used concomitantly with Quamatel slow down absorption of famotidine.

Concomitant use of Quamatel and drugs that inhibit medullary hematopoiesis increases the risk of neutropenia.

Special Instructions

The use of Quamatil may mask the symptoms of gastric cancer, so the presence of a malignant neoplasm should be excluded before starting treatment with Famotidine.

Famotidine may cause withdrawal if treatment is stopped abruptly, so treatment should be stopped by gradually reducing the dose.

Patients with impaired liver function should be prescribed with caution and in lower doses.

In long-term treatment of weakened patients or patients under stress, bacterial lesions of the stomach with further spread of infection are possible.

Quamatel should be taken 2 hours after taking itraconazole or ketoconazole to avoid significantly reducing their absorption. Also, a 1-2 hour break between taking Quamatel and antacids should be observed.

Histamine H2-receptor blockers (including Quamatel) may inhibit the acid-stimulating effects of pentagastrin and histamine; therefore, 24 hours before the test, Quamatel should not be prescribed.

Histamine H2-receptor blockers may suppress the cutaneous response to histamine, thus leading to false-negative results. Therefore, Quamatel should be discontinued before performing diagnostic skin tests to detect an immediate allergic skin reaction.

During treatment, consumption of food, beverages and other drugs that may cause irritation of the gastric mucosa should be avoided.

Impact on driving and operating machinery

Patients should be careful when driving vehicles and engaging in potentially hazardous activities requiring increased concentration and quick psychomotor reactions while taking Quamatel.

Contraindications

With caution: the drug should be prescribed in cases of renal and hepatic impairment and in cirrhosis with portosystemic encephalopathy in anamnesis.

Side effects

Digestive system disorders: dry mouth, nausea, vomiting, abdominal pain, flatulence, constipation, diarrhea, decreased appetite; increased liver transaminase activity, hepatocellular, cholestatic or mixed hepatitis, acute pancreatitis.

Hematopoietic system disorders: very rarely – agranulocytosis, pancytopenia, leukopenia, thrombocytopenia, bone marrow hypo- or aplasia.

Allergic reactions: urticaria, skin rash, pruritus, bronchospasm, angioedema, anaphylactic shock.

Cardiovascular system: arrhythmia, bradycardia, AV-blockade, decreased BP.

CNS disorders: headache, dizziness, somnolence, hallucinations, confusion, increased fatigue, depression, agitation, anxiety.

Sensory organs: decreased visual acuity, tinnitus.

Gender system disorders: with prolonged use in high doses – hyperprolactinemia, gynecomastia, amenorrhea, decreased libido.

Muscular system disorders: arthralgia, muscle cramps.

Dermatological reactions: alopecia, common acne, dry skin, toxic epidermal necrolysis.

Others: fever.

Overdose

Symptoms: vomiting, motor agitation, tremor, decreased BP, tachycardia, collapse.

Treatment: gastric lavage, symptomatic and supportive therapy; hemodialysis.

Similarities